As nucleoside analogues and topoisomerase inhibitors are the mainstay of AML therapy, we examined the toxicity of these drug classes as well as that of RP2 inhibitors against unmanipulated and dormancy-enriched KG1a cells. Here, RP2 is linked to acute myeloid leukemia.